Sernova Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	5.8yrs

Recent management updates

Recent updates

CEO

Sernova has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
James Parsons	CFO & Director	less than a year	CA$183.27k	0.12% $ 61.8k
Frank Shannon	Senior VP of Clinical Development and Regulatory Affairs	no data	CA$463.26k	no data
Modestus Obochi	Chief Business Officer	1.2yrs	CA$996.01k	0.015% $ 8.0k
Jonathan M. Rigby	Executive Chairman	less than a year	no data	no data
Douglas Maret	Chief Science Officer	no data	no data	no data
David Burke	Vice President of Investor Relations	less than a year	no data	no data
Marylyn Rigby	Chief Communications Officer	less than a year	no data	no data

0.2yrs

Average Tenure

Experienced Management: SEOV.F's management team is not considered experienced ( 0.2 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
James Parsons	CFO & Director	12.6yrs	CA$183.27k	0.12% $ 61.8k
Jonathan M. Rigby	Executive Chairman	less than a year	no data	no data
Norman C. Wong	Member of Scientific Advisory Board	18.3yrs	no data	no data
Jannette Dufour	Member of Scientific Advisory Board	18.3yrs	no data	no data
George King	Member of Scientific Advisory Board	no data	no data	no data
Clive Patience	Member of Scientific Advisory Board	17.9yrs	no data	no data
Steven Paraskevas	Member of Scientific Advisory Board	13.9yrs	no data	no data
Bernd Muehlenweg	Director	less than a year	no data	no data
David Lillicrap	Member of Scientific Advisory Board	5.8yrs	no data	no data
Anke Schulte	Member of Global Advisory Board	4.3yrs	no data	no data
Stephen Sangha	Independent Director	1.6yrs	CA$158.36k	4.01% $ 2.1m
Sam Wiseman	Member of Scientific Advisory Board	3.6yrs	no data	no data

5.8yrs

Average Tenure

57.5yo

Average Age

Experienced Board: SEOV.F's board of directors are considered experienced (5.8 years average tenure).

Sernova Management

Management criteria checks 1/4

Key information

Recent management updates

Sernova Corp. Appoints James Parsons as Chief Financial Officer

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

Sernova Corp., Annual General Meeting, Apr 30, 2024

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Recent updates

Sernova Corp. Appoints James Parsons as Chief Financial Officer

Sernova Corp. Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Sernova Corp. announced that it has received CAD 5.2 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

Sernova Corp., Annual General Meeting, Apr 30, 2024

Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress

Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting

Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™? at American Diabetes Association 83rd Scientific Sessions

Sernova Corp. Announces Executive Changes

Sernova Corp., Annual General Meeting, Apr 27, 2023

Sernova Announces Advancements with Its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Sernova Corp. Announces Executive Changes

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of Its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

Sernova Corp. Appoints Daniel Mahony, Ph.D. to Its Board of Directors, Effective from September 30, 2022

Sernova Corp. Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System Tm at American Diabetes Association 82nd Scientific Sessions 2022

Sernova Corp.(TSXV:SVA) dropped from S&P/TSX Venture Composite Index

Sernova Corp. announced that it has received CAD 20.323499 million in funding from Evotec SE

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation At American Diabetes Association 82Nd Scientific Sessions 2022

Sernova Corp., Annual General Meeting, Apr 28, 2022

Sernova Corp. Announces Publication of A Peer Reviewed Preclinical Study Demonstrating Positive Results of A Novel Cell Pouch System Cell Therapy

Sernova Corp. Provides Progress Update on Its Phase 1/2 T1d Clinical Trial

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference

Sernova Corp. has completed a Composite Units Offering in the amount of CAD 20.04 million.

Sernova Corp Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System Clinical Trial and Recommendation for Protocol Continuation

Sernova Corp. Announces Collaboration Agreements with Multiple Pharmaceutical Industry Leaders

Sernova Corp. Provides Clinical Update on U.S. Phase I/II Cell Pouch Trial for Type 1 Diabetes

Sernova Corp. announced that it has received CAD 3.6655 million in funding

Sernova Corp. announced that it expects to receive CAD 3 million in funding

CEO

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age